← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #218 OF 1,000 MOST-CITED

Lack of or inadequate procedures for labeling

FDA cited this observation 107 times across 103 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices107
BY FISCAL YEAR
FY20262
FY20254
FY20249
FY202312
FY202213
FY20215
FY20207
FY201919
FY201826
FY201710

How FDA worded it — real examples

Procedures to control labeling activities have not been adequately established.

Specialty Health Products CO, LLC · Phoenix, Arizona · Devices · 2025-12-11

Procedures to control labeling activities have not been established.

Medaesthetics International, LLC · Phoenix, Arizona · Devices · 2025-10-22

Procedures to control labeling activities have not been established.

RAC Medical Solutions · Bruceton, Tennessee · Devices · 2025-08-07

Procedures to control labeling activities have not been established.

Eyegaze Inc. · Fairfax, Virginia · Devices · 2025-05-02

Procedures to control labeling activities have not been established.

Poonglim Pharmatech Inc. · Gunsan · Devices · 2025-01-16

Procedures to control labeling activities have not been established.

DFI Co., Ltd. · Gimhae · Devices · 2025-01-09

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemMedical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →